Clinical trials
Unresectable Breast Cancer clinical trials
Below are recruiting unresectable breast cancer clinical trials, each written for real people, not researchers. We’re tracking 266 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05304962RecruitingPhase 1
Test drug RGT-419B for advanced ER+ HER2- breast cancer
This Phase 1 study tests a new drug (RGT-419B), given alone or with hormone (endocrine) therapy, in people with advanced ER-positive, HER2-negative breast cancer that has progressed after standard treatments. It looks mainly at safety and early signs of how well the treatment may work.
La Jolla, CaliforniaAges 18 years+ - NCT04965766RecruitingPhase 2
Study drug for HER2-negative, advanced breast cancer after prior treatment
This Phase 2 trial tests patritumab deruxtecan (U3-1402) in people with HER2-negative, hormone-receptor positive (HR+) breast cancer that cannot be removed by surgery or has spread. It’s for cancers that have progressed despite endocrine therapy plus a CDK4/6 inhibitor, aiming to shrink tumors and control the disease.
DijonAges 18 years+ - NCT05095207RecruitingPhase 1/Phase 2
Abemaciclib and bicalutamide for HER2-negative metastatic breast cancer
This Phase 1/2 trial tests whether combining abemaciclib with bicalutamide can slow or shrink HER2-negative, androgen receptor–positive (AR-positive) metastatic breast cancer. It mainly looks at safety and side effects, and also whether the combination can help patients with this type of breast cancer.
New York, New YorkAges 18–90 - NCT05098210RecruitingPhase 1
Personalized vaccine made from your tumor’s new immune targets
This Phase 1 study tests a customized vaccine made from “neo-antigens,” which are new targets found in your tumor. It aims to help your immune system fight certain advanced cancers that have not responded well to prior treatment.
Seattle, WashingtonAges 18 years+ - NCT05029999RecruitingPhase 1
Test drugs for HER2-negative advanced breast cancer
This Phase 1 trial tests a combination of immune-targeting drugs (a CD40 medicine and a substance that helps immune cells act) plus chemotherapy in people with HER2-negative advanced breast cancer that has progressed. It aims to find a safer dose and see whether the treatment can shrink tumors or slow the cancer.
Chicago, IllinoisAges 18–99 - NCT04968964Recruiting
Monitoring test for CDK4/6 drugs in metastatic breast cancer
This study follows people with hormone receptor–positive, HER2-negative metastatic breast cancer who are taking CDK4/6 inhibitor treatment (with or without an added blood test called DiviTum®). The goal is to see how well the standard treatment is working and whether DiviTum® (a serum TK1 activity test) can help guide monitoring.
St Louis, MissouriAges 18 years+ - NCT02830724RecruitingPhase 1/Phase 2
CAR T therapy using blood immune cells for CD70 cancers
This trial tests a personalized immune-cell treatment (CAR T) built from your own blood lymphocytes. It targets cancers that show a marker called CD70, aiming to slow or stop the cancer when other treatments didn’t work.
Bethesda, MarylandAges 18–72 - NCT02819882Recruiting
Registry study for advanced or metastatic breast cancer
This study collects health and treatment information from people with breast cancer that cannot be fully removed by surgery or that has spread to other parts of the body. It may help researchers better understand which treatments are used and how people do over time.
Elche, AlicanteAges 18 years+ - NCT07597629RecruitingPhase 2
SYS6023 combination therapy for advanced breast cancer
This trial tests a new drug combination (SYS6023) for advanced breast cancer that has spread or cannot be surgically removed. The treatment targets a protein called HER3, which may help stop cancer growth in patients whose cancer has progressed despite previous treatments.
Harbin, HeilonjiangAges 18 years+ - NCT06155305Recruiting
Organoid drug test before breast cancer surgery
This trial uses a lab-grown mini-tumor (organoid) from your biopsy to test which chemotherapy drugs work best for your cancer before you have surgery. The goal is to personalize your treatment and improve outcomes.
Hangzhou, ZhejiangAges 18–70 - NCT05816655RecruitingPhase 2
Test two hormone treatment combinations for metastatic breast cancer
This Phase 2 study compares two combinations of hormone-blocking drugs plus an anti-cancer targeted pill to see which works better for hormone-receptor positive, HER2-negative metastatic breast cancer. It may help by finding a more effective treatment plan when the cancer has spread.
SeoulAges 19–80 - NCT07037199RecruitingPhase 2
A new drug combo for HR+ advanced breast cancer
This trial tests a sequence of three drugs: first trastuzumab rezetecan (a targeted therapy), then a CDK4/6 inhibitor plus hormone therapy. It's for people with a type of breast cancer called HR-positive, HER2-low or ultra-low that has spread or come back and has already progressed on a CDK4/6 inhibitor and hormone therapy.
Guangzhou, GuangdongAges 18 years+ - NCT07008976RecruitingPhase 3
Testing TQB2102 versus standard treatment for HER2-positive advanced breast cancer
This trial tests a new drug called TQB2102 against a standard treatment (Kadcyla) for people with HER2-positive breast cancer that has spread or cannot be removed. It is for those whose cancer has worsened after previous HER2-targeted therapy.
Bengbu, AnhuiAges 18–75 - NCT06732323RecruitingPhase 3
Study of ESG401 for triple-negative breast cancer that has spread
This trial tests a new drug, ESG401, for people with triple-negative breast cancer that has come back or spread and cannot be removed by surgery. It compares ESG401 to standard chemotherapy options to see which works better.
BeijingAges 18 years+ - NCT06486883RecruitingPhase 2
T-DXd vs CDK4/6i plus hormone therapy for advanced HR-positive, HER2-low breast cancer
This trial compares two treatments for advanced breast cancer that is HR-positive, HER2-low or ultralow, and a non-luminal subtype. It tests if a targeted antibody-drug conjugate (T-DXd) works better than the usual first-line therapy combining a CDK4/6 inhibitor with hormone therapy. This study is for people who have not had any treatment for advanced disease.
GrazAges 18 years+ - NCT06081959RecruitingPhase 3
Study of SKB264 for advanced HR+/HER2- breast cancer
This trial tests a new drug called SKB264 for people with a common type of breast cancer (HR+/HER2-) that has spread or come back and has not responded to at least one round of chemotherapy. It aims to see if this treatment can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT05530057RecruitingPhase 2
Eribulin plus or minus trastuzumab for HER2-positive breast cancer
This trial tests whether adding trastuzumab to eribulin improves outcomes for people with HER2-positive breast cancer that has come back or spread. It’s meant for patients whose cancer has progressed after prior HER2 and chemotherapy treatments.
SeoulAges 18 years+ - NCT05831878Recruiting
Drug RC48 for HER2-low or HER2-ultralow breast cancer
This trial tests RC48, an antibody-drug treatment, for people with advanced breast cancer that cannot be cured or removed, specifically HER2-low (or HER2-ultralow) tumors. It may help by targeting cancer cells with this “HER2-low” trait while limiting spread in the body.
ShanghaiAges 18 years+ - NCT04174352RecruitingEarly Phase 1
FES scan to guide tamoxifen for metastatic breast cancer
This early-phase study uses a special PET scan (FES PET/CT) to better match tamoxifen treatment to people with estrogen-receptor–positive breast cancer that has spread. It aims to see whether the scan results can help optimize tamoxifen use and potentially improve outcomes.
Madison, WisconsinAges 19 years+ - NCT06663748RecruitingPhase 2
ARX788 for HER2-positive metastatic breast cancer
This trial studies a new drug called ARX788 for people with HER2-positive breast cancer that has spread or cannot be removed. It aims to see if the drug can shrink tumors and help patients live longer.
Zhengzhou, HenanAges 18–75 - NCT06471205RecruitingPhase 2
Study of BL-B01D1 plus immunotherapy for advanced triple-negative breast cancer
This study tests a new drug combination (BL-B01D1 plus an immunotherapy) for people with advanced triple-negative breast cancer who have not had prior treatment for their advanced disease. The goal is to see if the combination works better at shrinking or controlling the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06435351RecruitingEarly Phase 1
Personalized vaccine for high-risk triple-negative breast cancer
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) to help prevent your high-risk triple-negative breast cancer from coming back. It is for people who had significant tumor left after standard chemotherapy and surgery.
Tampa, FloridaAges 18 years+ - NCT04468061RecruitingPhase 2
Study chemo drug plus immunotherapy for metastatic triple-negative breast cancer
This trial tests sacituzumab govitecan (an antibody-drug medicine) with or without pembrolizumab (an immune-system therapy) in people with metastatic triple-negative breast cancer. It may help by shrinking tumors and improving immune control, especially for patients with specific tumor marker results.
Stamford, ConnecticutAges 18 years+ - NCT07238894Recruiting
Freezing and heating breast cancer without surgery
This study tests a combination of freezing and heating (cryoablation and thermal ablation) to treat breast cancer in patients who cannot have surgery. It may help shrink or control tumors while avoiding general anesthesia.
BeijingAges 18–80
Hear when a new Unresectable Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for unresectable breast cancer?
- Yes. Clin2 currently lists 266 recruiting unresectable breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a unresectable breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a unresectable breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.